Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Diltiazem. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1S known ✓ | Q13698 | 11/20 | 1.00 |
| ▸ | CACNA1F known ✓ | O60840 | 1/20 | 1.00 |
| ▸ | CACNA1D known ✓ | Q01668 | 1/20 | 1.00 |
| ▸ | CACNA1C known ✓ | Q13936 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | TSHR | P16473 | 2/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | LMNA | P02545 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | SLC22A1 | O15245 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | HRH2 | P25021 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | SCN1A | P35498 | 1/20 | 1.00 |
| ▸ | SCN4A | P35499 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | SCN7A | Q01118 | 1/20 | 1.00 |
| ▸ | PLAUR | Q03405 | 1/20 | 1.00 |
| ▸ | SCN5A | Q14524 | 1/20 | 1.00 |
| ▸ | SCN9A | Q15858 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diltiazem SCHEMBL3468378 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL29353951 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL17776 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127237 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL676914 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL614334 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL13575826 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL30127157 | 1.00 | CACNA1S (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL10831293 | 0.99 | CYP3A4 (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA | |
| Diltiazem SCHEMBL8545465 | 0.99 | CYP3A4 (1.00) | CACNA1SCYP3A4TSHRABCB11LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | claimed |
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NICOX S.A. | 2004-07-29 | — | — | US | claimed |
| US-6337325-B1 | IMMUNOSUPRESSANTS, AUTOIMMUNE DISEASES, DERMATITIS, RHINITIS, UVEITIS, ANTIDIABETIC AGENTS, CYSTIC FIBROSIS OR LIVER FIBROSIS | HOECHST AKTIENGESELLSCHAFT (DE) | 2002-01-08 | — | — | US | claimed |
| US-20170137439-A1 | sGC STIMULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2017-05-18 | — | — | US | disclosed |
| US-8709804-B2 | Method for drug screening and characterization by calcium flux | CEDARS-SINAI MEDICAL CENTER (US) | 2014-04-29 | — | — | US | disclosed |
| US-20080253641-A1 | Method for Drug Screening and Characterization by Calcium Flux | CEDARS-SINAI MEDICAL CENTER (US) | 2008-10-16 | — | — | US | disclosed |
| EP-1087953-B1 | NITRATE SALTS OF ANTIHYPERTENSIVE MEDICINES | NICOX SA (FR) | 2004-11-17 | — | — | EP | disclosed |
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NICOX S.A. | 2004-07-29 | — | — | US | disclosed |
| US-6645965-B1 | Sildenafil, hydralazine, minoxidil, or zaprinast; cardiovascular disorders | NICOX S.A. (FR) | 2003-11-11 | — | — | US | disclosed |
| US-6191152-B1 | CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS | EGIS GYÓGYSZERGYAR RT. (HU) | 2001-02-20 | — | — | US | disclosed |
| US-5543155-A | AMMONIUM METHACRYLATE COPOLYMER | EGIS GYOGYSZERGYAR RT. (HU) | 1996-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170137439-A1 | sGC STIMULATORS | PTGIS, CGAS, GUCY1A1 | CACNA1S 1364/4885CACNA1F 1588/4885CACNA1D 1625/4885 |
| US-20040147575-A1 | Nitrate salts of antihypertensive medicines | NOS2, NOS1, NOS3 | CACNA1S 105/4885CACNA1F 141/4885CACNA1D 196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.